Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc > DIAGNOCURE-HOLOGIC PROPOSED PCA3 ASSET SALE IS FLAWED
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(80)
•••
Comment by bingostaron Jan 08, 2016 10:03am
120 Views
Post# 24439819

RE:RE:DIAGNOCURE-HOLOGIC PROPOSED PCA3 ASSET SALE IS FLAWED

RE:RE:DIAGNOCURE-HOLOGIC PROPOSED PCA3 ASSET SALE IS FLAWEDMaybe the initial agreement could have been negotiated better but we will not change the past. One thing is sure the PCA3 royalties brings about 130K$/quarter or 520k$/year for Diagnocure. To get 11M$ now is not a bad deal considering the obsolescence of that technology and the cost to maintain the structure. On the other hand, I would pressure Hologic to make an offer andbring significant money on the table for the PCP that would be fair for Diagnocure shareholders.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities